DILD — Diffuse Interstitial Lung Diseases

ILD — Diffuse Interstitial Lung Diseases | Internal Medicine

How it begins

Referencia experta sobre el grupo más heterogéneo de las enfermedades pulmonares. Cubre la clasificación ATS/ERS actualizada, la fisiopatología de la fibrogénesis, los patrones tomográficos diagnósticos, las neumonías intersticiales idiopáticas (especialmente FPI), las EPID de causa conocida (ETC, NH, neumoconiosis), las granulomatosas (sarcoidosis), las raras (LAM, histiocitosis) y el manejo integral con…

What it covers

1. Classification and Nomenclature of DILDs
2. · ATS/ERS Classification 2013 (revised 2022)
3. Pathophysiology of Alveolar Damage, Inflammation and Fibrogenesis
4. · Normal Alveolar Unit and Response to Damage
5. · Physiopathological Consequences of Pulmonary Fibrosis
6. Clinical and Diagnostic Approach in DILD
7. · Clinical History Directed to DILD
8. · Functional Study in EPID
9. · Bronchoalveolar lavage (BAL) in DILD
10. Tomographic Patterns in DILD (TCAR)
11. · Essential Glossary of HRCT Signs in DILD
12. Idiopathic Pulmonary Fibrosis — Definition and Epidemiology
13. · Epidemiology and Risk Factors
14. FPI — Molecular Pathogenesis and Diagnostic Criteria ATS/ERS 2022
15. · Histopathology of the NIU Pattern
16. · HRCT Diagnostic Criteria for IPF (ATS/ERS/JRS/ALAT 2022)
17. Antifibrotic Treatment of IPF
18. · Nintedanib (Ofev®)
19. · Pirfenidone (Esbriet®)
20. · Comparison and Selection between Antifibrotics
21. NINE (NSIP) and NOC (COP)
22. · Non-Specific Interstitial Pneumonia (NINE / NSIP)
23. · Cryptogenic Organized Pneumonia (NOC / COP)
24. DIP · RB-ILD · Lymphoid Interstitial Pneumonia (LIP) · Alveolar Proteinosis
25. · DIP and RB-ILD (NII Related to Tobacco)
26. · Lymphoid Interstitial Pneumonia (NIL / LIP)
27. · Pulmonary Alveolar Proteinosis (PAP)
28. Diffuse Alveolar Damage (DAD) — AIN and Acute Exacerbation of IPF
29. · Diffuse Alveolar Damage (DAD): The Histological Substrate of ARDS
30. · Acute Exacerbation of IPF (AE-IPF)
31. ILD Associated with Connective Tissue Diseases (ILD-CTE)
32. Hypersensitivity Pneumonitis (HN)
33. · Causal antigens and etiology
34. Pneumoconiosis
35. Pulmonary Toxicity from Drugs and Radiation
36. Pulmonary Sarcoidosis
37. · Definition, Epidemiology and Radiological Staging
38. Langerhans Cell Histiocytosis and Lymphangioleiomyomatosis
39. · Pulmonary Langerhans Cell Histiocytosis (PLCH)
40. · Lymphangioleiomyomatosis (LAM)
41. Eosinophilic pneumonias
42. Vasculitis with Pulmonary Involvement and Diffuse Alveolar Hemorrhage
43. · Diffuse Alveolar Hemorrhage (DHA)
44. Pulmonary Hypertension in DILD and CPFE
45. · Pulmonary Hypertension Associated with ILD (WHO Group 3)
46. · CPFE — Combined Pulmonary Fibrosis and Emphysema
47. Lung Transplant in ILD and Diagnostic-Therapeutic Algorithms
48. · Lung Transplant in ILD
49. · Integrative Diagnostic Algorithm in EPID